Novel approach was well tolerated in combination with neoadjuvant therapy
— Novel approach was well tolerated in combination with neoadjuvant therapy
by Gregory Laub, Senior Director, Video, MedPage Today
July 8, 2026
• 3 min read
At the American Society of Clinical Oncology (ASCO) meeting, phase II findings suggested that intratumoral dendritic cell therapy combined with HER2-targeted treatment may enhance immune activity and improve pathologic complete response rates in patients with early-stage HER2-positive breast cancer.
After neoadjuvant therapy, ctDNA clearance occurred in 96% of patients
New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment
Jame Abraham, MD, discusses how DESTINY-Breast11 may reshape care
How data from HER2CLIMB-05 and PATINA are influencing treatment decisions
Experts discuss oral SERDs, novel targeted combinations, and sequencing
Experts discuss the DESTINY-Breast11 and DESTINY-Breast05 results in high-risk disease
